Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
Prasugrel was associated with a statistically significant reduction in rates of cardiac ischemic events in patients with ACS who had undergone PCI. Rates of post-PCI death from cardiovascular causes, nonfatal MI, or nonfatal stroke were also significantly reduced with the use of prasugrel versus clopidogrel. Major bleeding was significantly increased with the use of prasugrel versus clopidogrel. Mortality did not differ significantly between the groups.
Solomon
Scott
S
The University of Kansas Medical Center and Hospital, 39th and Rainbow Blvd., Kansas City, KS 66106, USA. csolomon@kumc.edu
Vacek
James L
JL
D006801:Humans; D054058:Acute Coronary Syndrome / Q000150:complications / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D016001:Confidence Intervals; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D010879:Piperazines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D000068799:Prasugrel Hydrochloride; D011725:Pyridines / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D016032:Randomized Controlled Trials as Topic
D001241:Aspirin; D000077144:Clopidogrel; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D000068799:Prasugrel Hydrochloride; D011725:Pyridines; C446540:thienopyridine; D013876:Thiophenes; D013988:Ticlopidine